– USA, MA – Privo Technologies Inc. today announced the appointment of Dr. Albert Collinson (Ph.D) to its Board as an Independent Non-Executive Director.
“We are thrilled to welcome him as an Independent Non-Executive Director. His unrivaled expertise and extensive industry network will undoubtedly enhance our ability to drive innovation and unlock new opportunities in the life sciences sector. We look forward to leveraging his insights and strategic guidance as we continue to advance our mission of improving human health through cutting-edge technologies,” said CEO and Founder, Dr. Manijeh Goldberg.
About Dr. Albert Collinson
Dr. Albert Collinson, a distinguished industry expert and former Business Development Advisor to Privo Technologies, brings a wealth of experience and expertise to his new role.
Dr. Albert Collinson has over 35 years of experience in the pharmaceutical and biotechnology industries. He was the president and CEO at Theracos, Inc. from July 2009 to July 2023, a pharmaceutical research and development company focusing on mid to late-stage assets for the treatment of human diseases including type-2 diabetes. In July 2023, their asset Brenzavvy was approved for commercial use.
Before Theracos Inc., Dr. Collinson founded and served as president and CEO of Opsonic Therapeutics from 2009 to June 2014, a privately held biotechnology company engaged in the development of the next generation of antibody therapeutics. Dr. Collinson also served as CBO of Rib-X Pharmaceuticals from 2004 to 2009, the senior vice president of business development at Phylos, Inc. from 2000 to 2004, and the vice president of global research & development licensing at BASF Pharma from 1998 to 2000. Dr. Collinson began his career as a scientist at ImmunoGen, Inc.
Dr. Collinson said, “I am honored to join Privo Technologies Inc. as an Independent Non-Executive Director. Having been involved with the company as a Business Development Advisor for several years, I have witnessed firsthand the dedication and innovation that define Privo’s culture. Privo’s existing products target rare diseases with significant unmet medical need providing patients with more safe and efficacious treatment options. Privo’s intratumoral injectable derivative of the PRV Platform is one to watch as it provides patients diagnosed with aggressive cancers a single treatment injection with a sustained release profile of over 1 month with preclinical data supporting not only tumor control but tumor shrinkage and, in some cases, full regression. I am excited to contribute to the company’s ongoing success by supporting the development of its assets and helping to shape its future strategic direction.”
About Privo Technologies, Inc.
Privo Technologies, Inc. is a phase 3 clinical-stage biopharmaceutical company committed to developing innovative therapeutics designed to eliminate cancers and prevent recurrence. Privo aims to provide better and more accessible treatment options to diverse patient populations around the world with the potential to transform the standard of care for treating solid tumors. Privo is headquartered in Peabody, a suburb of Boston, Massachusetts.
SOURCE: https://privotechnologies.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.